Abiomed had a rough 2019, and their stock declined substantially because of it. The FDA warned that Abiomed's flagship product had an "increased rate of mortality", which stunted their revenue growth and collapsed their stock price. Instead of fighting the FDA, Abiomed worked with them to determine how these increased mortality rates occurred. Later in 2019, they confirmed … [Read more...] about Abiomed’s Heart Could Be In The Right Place